Inion researchers push back boundaries
Cambridge researchers working for a Finnish company specialising in biodegradeable implants are pushing back the boundaries of the technology with work on next-generation material.Cambridge researchers working for a Finnish company specialising in biodegradeable implants are pushing back the boundaries of the technology with work on next-generation material.
Central to Science Park company Inion’s longer-term growth strategy is the development and subsequent roll-out of biodegradable implants made from the next-generation Inion
OptimaPLUSTM material, which combines bioactivity with biodegradability. The successful development of this technology will be a key differentiator between Inion products and those of its competitors and therefore the company remains clearly focused on and committed financially to driving this important programme forward as rapidly as possible.
The desire to develop its third-generation platform in a timely fashion is a key factor in the increased R&D investment that Inion has seen in the first half of 2006.
Announcing its interim results, Inion said: ‘Our researchers in the European Technical Centre in Cambridge are making important progress towards demonstrating the mode of action and clinical proof of principle of this exciting new material and we expect to deliver the first clinical results in Q1 and Q2 2007, respectively.”
To further accelerate its research into novel bioactive and biodegradable material technologies, Inion is seeking additional grant funding and expects to hear the outcome of several applications before the end of 2006.
Inion boosted interim sales 23 per cent to £2.5m but pre-tax losses climbed 25 per cent to £4m in line with higher R & D spend and one-off reorganisation costs.
Inion’s core expertise and technology lies in the design and manufacture of innovative biodegradable plates, screws, pins and membranes that are used to enhance the healing of skeletal injuries (bone and soft tissue), such as those caused by trauma or by reconstructive surgery.
Inion implants are made from its proprietary Inion OptimaTM family of biomaterials, with properties tailored for specific surgical applications, in terms of strength, flexibility and rate of degradation.
Inion has developed and launched products in five strategic business areas – cranio-maxillofacial surgery, orthopaedic trauma, sports medicine, dental surgery and most recently in the spinal implant area – in nearly 50 countries worldwide.The company has operations in the UK at Takeley in Essex and Cambridge Science Park.